Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,341 | 1,100 | 99.5% |
| Education | $72.49 | 10 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,827 | 137 | $0 (2024) |
| Gilead Sciences, Inc. | $1,205 | 81 | $0 (2024) |
| Amgen Inc. | $1,097 | 84 | $0 (2024) |
| PFIZER INC. | $1,035 | 70 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $969.93 | 81 | $0 (2023) |
| Allergan, Inc. | $804.71 | 79 | $0 (2020) |
| Lilly USA, LLC | $788.34 | 56 | $0 (2024) |
| GlaxoSmithKline, LLC. | $760.62 | 56 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $734.64 | 46 | $0 (2024) |
| Novo Nordisk Inc | $648.24 | 42 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,922 | 118 | ABBVIE INC. ($330.69) |
| 2023 | $2,064 | 139 | AbbVie Inc. ($518.86) |
| 2022 | $1,875 | 136 | ABBVIE INC. ($347.81) |
| 2021 | $2,505 | 182 | AbbVie Inc. ($294.75) |
| 2020 | $2,137 | 144 | Allergan, Inc. ($368.71) |
| 2019 | $1,764 | 149 | Gilead Sciences, Inc. ($252.76) |
| 2018 | $1,743 | 130 | Takeda Pharmaceuticals U.S.A., Inc. ($229.12) |
| 2017 | $1,404 | 112 | Takeda Pharmaceuticals America, Inc. ($165.24) |
All Payment Transactions
1,110 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $8.21 | General |
| 12/17/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $32.64 | General |
| Category: HIV | ||||||
| 12/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.03 | General |
| Category: NEUROSCIENCE | ||||||
| 12/13/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $9.65 | General |
| Category: RESPIRATORY | ||||||
| 12/12/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: Diabetes | ||||||
| 12/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: PAIN | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: RESPIRATORY | ||||||
| 12/04/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 11/27/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: Gastroenterology | ||||||
| 11/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: Oncology | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $11.25 | General |
| Category: RESPIRATORY | ||||||
| 11/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: PAIN | ||||||
| 11/11/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $8.71 | General |
| Category: Inflammation | ||||||
| 11/06/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Diabetes Care | ||||||
| 11/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: PSYCHIATRY | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.31 | General |
| 10/31/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 10/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: DIABETES | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: RESPIRATORY | ||||||
| 10/14/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 705 | 904 | $111,775 | $71,284 |
| 2022 | 8 | 630 | 859 | $102,585 | $66,640 |
| 2021 | 7 | 585 | 809 | $97,275 | $61,384 |
| 2020 | 7 | 644 | 899 | $86,200 | $46,034 |
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 265 | 437 | $48,070 | $26,016 | 54.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 195 | 195 | $29,250 | $25,142 | 86.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 89 | 112 | $17,920 | $10,040 | 56.0% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 29 | 29 | $5,800 | $4,771 | 82.3% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 15 | 15 | $3,000 | $2,478 | 82.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $1,680 | $983.73 | 58.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 17 | 19 | $1,425 | $818.82 | 57.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 59 | 61 | $3,590 | $546.14 | 15.2% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 13 | 13 | $930.00 | $450.06 | 48.4% |
| 81002 | Urinalysis, manual test | Office | 2023 | 11 | 11 | $110.00 | $37.51 | 34.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 258 | 451 | $49,610 | $28,739 | 57.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 164 | 164 | $24,600 | $21,664 | 88.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 95 | $15,200 | $7,894 | 51.9% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2022 | 21 | 21 | $4,200 | $3,536 | 84.2% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 16 | 16 | $3,200 | $2,695 | 84.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 23 | 25 | $1,875 | $1,073 | 57.2% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 19 | 39 | $780.00 | $634.23 | 81.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 47 | 48 | $3,120 | $404.65 | 13.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 280 | 475 | $52,070 | $31,096 | 59.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 120 | 120 | $18,050 | $16,225 | 89.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 101 | 124 | $19,560 | $9,951 | 50.9% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2021 | 17 | 17 | $3,500 | $2,916 | 83.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 16 | 19 | $1,410 | $730.70 | 51.8% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 38 | 39 | $2,535 | $412.76 | 16.3% |
| 81002 | Urinalysis, manual test | Office | 2021 | 13 | 15 | $150.00 | $52.20 | 34.8% |
About Dr. Charles Byrd, MD
Dr. Charles Byrd, MD is a Family Medicine healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225056328.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Byrd, MD has received a total of $15,414 in payments from pharmaceutical and medical device companies, with $1,922 received in 2024. These payments were reported across 1,110 transactions from 68 companies. The most common payment nature is "Food and Beverage" ($15,341).
As a Medicare-enrolled provider, Byrd has provided services to 2,564 Medicare beneficiaries, totaling 3,471 services with total Medicare billing of $245,340. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Other Specialties Family Medicine
- Location Austin, TX
- Active Since 07/17/2006
- Last Updated 07/27/2011
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1225056328
Products in Payments
- VRAYLAR (Drug) $1,115
- NURTEC ODT (Drug) $729.20
- JARDIANCE (Drug) $626.34
- XIFAXAN (Drug) $534.63
- TRINTELLIX (Drug) $520.23
- UBRELVY (Drug) $516.36
- Aimovig (Biological) $508.79
- EMGALITY (Drug) $508.42
- TRELEGY ELLIPTA (Drug) $456.97
- Trintellix (Drug) $401.58
- Otezla (Drug) $344.72
- QULIPTA (Drug) $294.88
- Ozempic (Drug) $283.94
- AJOVY (Biological) $273.33
- UNITHROID (Drug) $260.74
- Rybelsus (Drug) $257.03
- CHANTIX (Drug) $226.85
- SYMBICORT (Drug) $215.25
- Repatha (Biological) $211.18
- LINZESS (Drug) $168.55
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Austin
Dr. Cynthia Brinson, M.d, M.D
Family Medicine — Payments: $533,082
Dr. David Wright, M.d, M.D
Family Medicine — Payments: $151,266
James Hahn, Md, MD
Family Medicine — Payments: $45,324
Rodolfo Alamia, Md, MD
Family Medicine — Payments: $44,627
Dr. Nomita Kim, Md, MD
Family Medicine — Payments: $39,549
Mr. Eric Perez, Fnp-C, FNP-C
Family Medicine — Payments: $32,768